EventsThe 1st International Electronic Conference on Pharmaceutics
Published
This submission belongs to the session A. Formulation of Poorly Soluble Drugs of the event The 1st International Electronic Conference on Pharmaceutics
Published date
01 Dec, 2020
Citation
Thomas Rades, Investigating to optimal ratio between drug and co-former in co-amorphous systems, in Proceedings of The 1st International Electronic Conference on Pharmaceutics, 1 December–15 December 2020, MDPI: Basel, Switzerland, doi: 10.3390/IECP2020-08764
Share
Email
Facebook
Twitter
LinkedIn

Investigating to optimal ratio between drug and co-former in co-amorphous systems

image
1. Copenhagen University, Denmark
Abstract

Most new low molecular weight chemical entities in pharmaceutical developments suffer from a low aqueous solubility, making oral delivery challenging. Despite the numerous formulation efforts that can be investigated, research especially on amorphous drugs and formulations appears to be a useful approach. Whilst few drugs can be converted to an amorphous form on their own, due to a too physical stability, the use of amorphous solid dispersions, i.e. the dissolution of drug molecules into (amorphous) polymers is increasingly used. However, certain shortcoming of these polymers based amorphous solid dispersions, such as a low drug load and a usually high hygroscopicity; still necessitate the investigation of alternative approaches. One such approach is the use of co-amorphous systems, i.e. to combination of initially crystalline low molecular weight drugs and excipients. Usually here a 1:1 molar ratio is used, but this may not be the optimal mixing ratio. In this presentation, work on investigating to optimal ratio between drug and co-former will be presented and critically discussed.

Keywords
amorphous
co-amorphous
poor water solubility
Manuscript
Poster
Slides_eConference_Thomas_Rades_final.pdf
Development of Intranasal Chitosan-Based Drug Delivery Containing Meloxicam
Development of a Novel Oral Amphotericin B Formulation (iCo-019) to Treat Systemic Fungal and Parasitic Infections